Ramy Farid

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
New York, NY
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ramy Farid

Form 4 holding Director

Structure Therapeutics Inc.

Security class
American Depositary Shares
Shares / value
275,000
Estimated value
$17,176,500
Report date
07 Feb 2023
Price
$62.46
Ownership
By Schrodinger, Inc.
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Vir Biotechnology, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
16,000
Estimated value
$24,480
Report date
27 May 2026
Price
$1.53
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President & CEO, Director

Schrodinger, Inc.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
17 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Structure Therapeutics Inc.

Security class
Series B Preferred Shares
Shares / value
0
Estimated value
Report date
07 Feb 2023
Price
Ownership
By Schrodinger, Inc.
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Ramy Farid

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .